地西他滨治疗骨髓增生异常综合征和急性髓系白血病的临床观察

Clinical Observation of Decitabine in the Treatment of Patients With Bone Marrow Hyperplasia Syndrome and Acute Myeloid Leukemia

目的探讨地西他滨治疗骨髓增生异常综合征(MDS)和急性髓系白血病(AML)的效果。方法随机将60例MDS/AML患者分为两组,对照组单纯行地西他滨治疗,观察组在对照组的基础上联合全程CAG方案治疗。比较两组临床效果。结果对照组的治疗有效率为63.33%,观察组的有效率为50.0%,组间数据差异无统计学意义(t=0.785,P>0.05);对照组存活率为83.33%,观察组存活率为86.67%,组间数据差异无统计学意义(t=0.785,P>0.05)。结论地西他滨单独用药或联合CAG方案治疗MDS/AML效果都很理想。

Objective To investigate the treatment effect of decitabine for myelodysplastic syndrome（MDS） and acute myeloid leukemia（AML）, Methods 60 patients with MDS and AML were divided into two groups. Control group was used about decitabine, observation group which is on the basis of the control group received CAG regimen, to compare the treatment effect of two groups. Results The effective rate of control group was 63.33%, that of observation group was 50.0%, the difference has nostatistical significance（t=0.785, P〈0.05）, the survival rate of control gr was 83.33%, that of the observation group was 86.67%, the difference no statistical significance（t=0.785, P〈0.05）. Conclusion The treatm effect of patients with MDS/AML receiving decitabine alone o combination with CAG regimen is ideal.